바이오콘 바이오로직스, 비아트리스 바이오시밀러 사업 통합 완료…세계 최대 기업으로 부상

Biocon's scale in biosimilars positions India as the global hub for affordable biologics, potentially transforming access to cancer and autoimmune treatments across developing Asia.

Saturday, February 7, 2026
2 min read
Biocon Press Release
정규 소스
India
Full Analysis85%
LinkedInX
변경 사항

Biocon Biologics completed integrating Viatris's biosimilars business, creating the world's largest pure-play biosimilars company with 20+ molecules and commercial presence in 120+ countries.

Key Figures
20+ moleculesThe combined entity has a portfolio of 20+ molecules.
120+ countriesThe combined entity has a commercial presence in 120+ countries.
$2.1 billionThe combined entity reported annualized revenue of $2.1 billion.
Source Report

Biocon Biologics 完成了 Viatris 生物仿制药业务的整合,成为全球最大的纯生物仿制药公司。

Sigvera Intelligence
1World's largest pure-play biosimilars company with 20+ molecules
2Commercial presence in 120+ countries
3Annualized revenue of $2.1 billion
Market Impact

Biocon's scale in biosimilars positions India as the global hub for affordable biologics, potentially transforming access to cancer and autoimmune treatments across developing Asia.

Healthtech & Biotech

Where this signal fits in the broader landscape.

Partnership
전체 보기
전체 보기

No recent signals tracked yet.

Verified from official source
PublisherBiocon Press Release
게시일Feb 7, 2026
소스 유형Company Newsroom
소스 분류Verified Canonical
시그널 타임라인
최초 보도Feb 7, 2026
인덱싱Feb 8, 2026
게시Feb 9, 2026

https://www.bioconbiologics.com/our-stories/biocon-biologics-successfully-completes-integration-of-acquired-biosimilars-business-in-120-countries/

Read Full Source
신뢰도:90%
Get cross-language signal intelligence

Get curated intelligence delivered to your inbox. No spam, unsubscribe anytime.

Sign in to save notes on signals.

로그인
기업Biocon산업Healthtech & Biotech지역India이벤트Partnership출처공식

Stay ahead of the next signal.

Free weekly briefings with structured signal summaries. No spam, cancel anytime.